Business Daily from THE HINDU group of publications
Friday, Jul 21, 2006


News
Features
Stocks
Cross Currency
Shipping
Archives
Google

Group Sites

Corporate - Regulatory Bodies & Rulings
Glenmark gets nod for Meloxicam

Our Bureau

Mumbai, July 20

Glenmark Pharmaceuticals Ltd has received the US Food and Drug Administration (USFDA) approval to market Meloxicam oral tablets 7.5 mg and 15 mg.

Meloxicam is the generic version of Boehringer Ingelheim's brand Mobic and is used to treat osteoarthritis.

The drug has clocked annual sales of about $936 million, according to a note from Glenmark. The generic drug will be marketed by Glenmark's US subsidiary, Glenmark Pharmaceutical Inc, which will commence supplying the drug to customers in the US immediately. Glenmark is manufacturing the drug at its solid-oral formulation facility at Goa. This is the third Abbreviated New Drug Application filed by Glenmark from the Goa facility, that has received USFDA approval.

More Stories on : Regulatory Bodies & Rulings | Pharmaceuticals

Article E-Mail :: Comment :: Syndication :: Printer Friendly Page



Stories in this Section
Tata Daewoo develops LNG trailer


BHEL bags Rs 46-cr order in Ethiopia
NCDEX gets `CCR AA' rating
ONGC mulls competitive financial packages for key staff
Havell's Q1 net profit up 81 pc
Taj group plans boutique hotel in Pune palace property
Thermax plans additional unit at Vadodara
Sona Group to set up subsidiary in France for exports
USFDA approval for Zydus drug
Glenmark gets nod for Meloxicam
Hyundai Motor India signs 3-year wage pact
BPCL to supply RLNG to FACT
Ranbaxy signs licensing pact for Canadian market
International Recreation ties up with Turner for Noida park
Karnataka Bank in financing pact
`We've improved our market share to 11.5 pc'
ACC Faridabad unit gets ISO 14001
Centre sanctions Rs 44 cr for Hind Antibiotics revival scheme
Nuclear major Areva calls India `first priority' market
VVF eyeing Rs 1,000-cr turnover in 2 years


The Hindu Group: Home | About Us | Copyright | Archives | Contacts | Subscription
Group Sites: The Hindu | Business Line | Sportstar | Frontline | The Hindu eBooks | The Hindu Images | Home |

Copyright 2006, The Hindu Business Line. Republication or redissemination of the contents of this screen are expressly prohibited without the written consent of The Hindu Business Line